Privi Speciality Chemicals Limited — Investor Meet, 16-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Privi Specialty Chemicals delivered robust financial results for the quarter and nine months ending December 31, 2025, with revenue up 25% and 24% YoY respectively. EBITDA margins held strong above 25%. Management announced a 3-phase, INR 1,200 Cr expansion to increase capacity by 55%, including new specialty products like bio-Cyclopentanone. The Givaudan JV achieved positive EBITDA and received a non-interest-bearing trade advance. The company targets INR 5,000 Cr revenue and INR 1,000 Cr+ EBITDA in 3-4 years, projecting 11-15% volume growth and sustained 20%+ margins. This strategic focus on innovation and efficiency positions the company for continued growth.